Q3-osavuosiraportti
21 päivää sitten‧1 t 1 min
Tarjoustasot
Määrä
Osto
208
Myynti
Määrä
35
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 3.11. | |
| 2025 Q2-osavuosiraportti | 6.8. | |
| 2025 Yhtiökokous | 12.6. | |
| 2025 Q1-osavuosiraportti | 1.5. | |
| 2024 Q4-osavuosiraportti | 19.2. |
Datan lähde: Morningstar, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 päivää sittenAbbott Laboratories has entered into an agreement to acquire cancer screening company Exact Sciences, valuing Exact at around 21 billion dollars, Bloomberg reports. This corresponds to 214 billion kroner. The acquisition will be one of the largest in the healthcare sector this year. Previously, Blackstone and TPG acquired Hologic for 18.3 billion dollars, while Johnson & Johnson acquired Intra-Cellular Therapies for more than 14 billion dollars. It recently became known that Novartis is acquiring Avidity Biosciences for 12.0 billion dollars. Chicago-based Abbott is paying 105 dollars per share in Exact Sciences, 51 percent more than Exact's closing price Tuesday this week, which was the last full trading day Bloomberg reported on a possible deal.
28.3.202428.3.2024Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer. Results indicate potential of a minimally invasive screening tool to detect most common form of Esophageal Cancer, a highly treatable cancer if caught early. Source: Business Wire- 19.11.2023 · Muokattu19.11.2023 · MuokattuProfitability Is Still Two Years Out. Today (Nov. 1, 2023), Exact Sciences is still reporting losses. But that's expected to change in 2025. At that point, analysts polled by FactSet expect the company to report an adjusted gain of 56 cents per share. Sales in 2023-25 are expected to grow 13%-15%. EXAS stock also has a nearly perfect Relative Strength Rating of 98. This puts shares in the top 2% of all stocks in terms of 12-month performance, according to IBD Digital. Shares also have a strong Composite Rating of 95, meaning EXAS stock outranks 95% of all stocks when it comes to fundamental and technical measures. Source: https://www.investors.com/news/technology/exas-stock-why-this-top-stock-is-on-an-eight-month-hot-streak/
- 5.11.20235.11.2023WHY EXAS COULD SOON BECOME PROFITABLE. "Looking forward, it remains to be seen if the robust Cologuard business momentum will continue or if the company's rising expenditures will pressure (or limit) margins in the near term," Canaccord's Mikson said. He kept his buy rating and 120 price target on EXAS stock. This is the first quarter since March 2021 that Exact Sciences hasn't reported an adjusted loss. Sales climbed 20% year over year. In the September quarter, sales in Exact Sciences' screening division surged 31% to $472 million. That beat EXAS stock analysts' view by $10 million, according to FactSet. The screening segment includes primarily laboratory service revenue from Cologuard and blood-based genetic tests that screen for hereditary forms of cancer called PreventionGenetics. "The solid results were driven by continued Cologuard volume growth, with revenue from this product increasing roughly 30% year over year," Canaccord Genuity analyst Kyle Mikson said in a report to clients. Source: https://www.investors.com/news/technology/exas-stock-why-this-large-cathie-wood-holding-could-soon-be-profitable/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
21 päivää sitten‧1 t 1 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 päivää sittenAbbott Laboratories has entered into an agreement to acquire cancer screening company Exact Sciences, valuing Exact at around 21 billion dollars, Bloomberg reports. This corresponds to 214 billion kroner. The acquisition will be one of the largest in the healthcare sector this year. Previously, Blackstone and TPG acquired Hologic for 18.3 billion dollars, while Johnson & Johnson acquired Intra-Cellular Therapies for more than 14 billion dollars. It recently became known that Novartis is acquiring Avidity Biosciences for 12.0 billion dollars. Chicago-based Abbott is paying 105 dollars per share in Exact Sciences, 51 percent more than Exact's closing price Tuesday this week, which was the last full trading day Bloomberg reported on a possible deal.
- 28.3.202428.3.2024Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer. Results indicate potential of a minimally invasive screening tool to detect most common form of Esophageal Cancer, a highly treatable cancer if caught early. Source: Business Wire
- 19.11.2023 · Muokattu19.11.2023 · MuokattuProfitability Is Still Two Years Out. Today (Nov. 1, 2023), Exact Sciences is still reporting losses. But that's expected to change in 2025. At that point, analysts polled by FactSet expect the company to report an adjusted gain of 56 cents per share. Sales in 2023-25 are expected to grow 13%-15%. EXAS stock also has a nearly perfect Relative Strength Rating of 98. This puts shares in the top 2% of all stocks in terms of 12-month performance, according to IBD Digital. Shares also have a strong Composite Rating of 95, meaning EXAS stock outranks 95% of all stocks when it comes to fundamental and technical measures. Source: https://www.investors.com/news/technology/exas-stock-why-this-top-stock-is-on-an-eight-month-hot-streak/
- 5.11.20235.11.2023WHY EXAS COULD SOON BECOME PROFITABLE. "Looking forward, it remains to be seen if the robust Cologuard business momentum will continue or if the company's rising expenditures will pressure (or limit) margins in the near term," Canaccord's Mikson said. He kept his buy rating and 120 price target on EXAS stock. This is the first quarter since March 2021 that Exact Sciences hasn't reported an adjusted loss. Sales climbed 20% year over year. In the September quarter, sales in Exact Sciences' screening division surged 31% to $472 million. That beat EXAS stock analysts' view by $10 million, according to FactSet. The screening segment includes primarily laboratory service revenue from Cologuard and blood-based genetic tests that screen for hereditary forms of cancer called PreventionGenetics. "The solid results were driven by continued Cologuard volume growth, with revenue from this product increasing roughly 30% year over year," Canaccord Genuity analyst Kyle Mikson said in a report to clients. Source: https://www.investors.com/news/technology/exas-stock-why-this-large-cathie-wood-holding-could-soon-be-profitable/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
208
Myynti
Määrä
35
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 3.11. | |
| 2025 Q2-osavuosiraportti | 6.8. | |
| 2025 Yhtiökokous | 12.6. | |
| 2025 Q1-osavuosiraportti | 1.5. | |
| 2024 Q4-osavuosiraportti | 19.2. |
Datan lähde: Morningstar, Quartr
Q3-osavuosiraportti
21 päivää sitten‧1 t 1 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 3.11. | |
| 2025 Q2-osavuosiraportti | 6.8. | |
| 2025 Yhtiökokous | 12.6. | |
| 2025 Q1-osavuosiraportti | 1.5. | |
| 2024 Q4-osavuosiraportti | 19.2. |
Datan lähde: Morningstar, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 päivää sittenAbbott Laboratories has entered into an agreement to acquire cancer screening company Exact Sciences, valuing Exact at around 21 billion dollars, Bloomberg reports. This corresponds to 214 billion kroner. The acquisition will be one of the largest in the healthcare sector this year. Previously, Blackstone and TPG acquired Hologic for 18.3 billion dollars, while Johnson & Johnson acquired Intra-Cellular Therapies for more than 14 billion dollars. It recently became known that Novartis is acquiring Avidity Biosciences for 12.0 billion dollars. Chicago-based Abbott is paying 105 dollars per share in Exact Sciences, 51 percent more than Exact's closing price Tuesday this week, which was the last full trading day Bloomberg reported on a possible deal.
- 28.3.202428.3.2024Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer. Results indicate potential of a minimally invasive screening tool to detect most common form of Esophageal Cancer, a highly treatable cancer if caught early. Source: Business Wire
- 19.11.2023 · Muokattu19.11.2023 · MuokattuProfitability Is Still Two Years Out. Today (Nov. 1, 2023), Exact Sciences is still reporting losses. But that's expected to change in 2025. At that point, analysts polled by FactSet expect the company to report an adjusted gain of 56 cents per share. Sales in 2023-25 are expected to grow 13%-15%. EXAS stock also has a nearly perfect Relative Strength Rating of 98. This puts shares in the top 2% of all stocks in terms of 12-month performance, according to IBD Digital. Shares also have a strong Composite Rating of 95, meaning EXAS stock outranks 95% of all stocks when it comes to fundamental and technical measures. Source: https://www.investors.com/news/technology/exas-stock-why-this-top-stock-is-on-an-eight-month-hot-streak/
- 5.11.20235.11.2023WHY EXAS COULD SOON BECOME PROFITABLE. "Looking forward, it remains to be seen if the robust Cologuard business momentum will continue or if the company's rising expenditures will pressure (or limit) margins in the near term," Canaccord's Mikson said. He kept his buy rating and 120 price target on EXAS stock. This is the first quarter since March 2021 that Exact Sciences hasn't reported an adjusted loss. Sales climbed 20% year over year. In the September quarter, sales in Exact Sciences' screening division surged 31% to $472 million. That beat EXAS stock analysts' view by $10 million, according to FactSet. The screening segment includes primarily laboratory service revenue from Cologuard and blood-based genetic tests that screen for hereditary forms of cancer called PreventionGenetics. "The solid results were driven by continued Cologuard volume growth, with revenue from this product increasing roughly 30% year over year," Canaccord Genuity analyst Kyle Mikson said in a report to clients. Source: https://www.investors.com/news/technology/exas-stock-why-this-large-cathie-wood-holding-could-soon-be-profitable/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
208
Myynti
Määrä
35
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt